Mr. Andre Larente reports

DIAGNOS ANNOUNCES CLOSING OF PRIVATE PLACEMENT

Diagnos Inc. has closed a non-brokered private placement of 1,828,717 units, issued at a price of 35 cents per unit, for gross proceeds of $640,050.95.

Each unit consists of:

• One common share;
• One-half common share warrant.

Each whole warrant can be exercised to purchase one share at a price of 45 cents per share for a period of 18 months ending June 4, 2025. An aggregate number of 914,356 warrants have been issued as part of the private placement.

The net proceeds from the private placement will be used to finance product development and commercialization of artificial-intelligence-based screening services as well as general and administrative operations.

In connection with the closing of the private placement, the corporation has committed to pay a cash commission of $11,250 to one qualified firm acting at arm's length, Optimista Consulting Services Inc.

All securities issued as part of the private placement are subject to a statutory hold period ending April 5, 2024.

The private placement remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as execution of formal documentation.

All moneys quoted in this press release shall be stated and paid in lawful money of Canada.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its Flaire artificial intelligence (AI) platform. Flaire allows for quick modifying and developing of applications such as CARA (computer-assisted retina analysis). Cara's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.

We seek Safe Harbor.